Canigen L4
Canine leptospirosis vaccine (inactivated)
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Canigen L4. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Canigen L4.
For practical information about using Canigen L4, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Authorisation details
Product details | |
---|---|
Name |
Canigen L4
|
Agency product number |
EMEA/V/C/004079
|
Active substance |
Inactivated Leptospira strains: L. interrogans serogroup Canicola serovar Portland-vere (strain Ca-12-000); L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni (strain Ic-02-001); L. interrogans serogroup Australis serovar Bratislava (strain As-05-073); L. kirschneri serogroup Grippotyphosa serovar Dadas (strain Gr-01-005)
|
International non-proprietary name (INN) or common name |
Canine leptospirosis vaccine (inactivated)
|
Species |
Dogs
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI07AB01
|
Publication details | |
---|---|
Marketing-authorisation holder |
Intervet International B.V.
|
Revision |
3
|
Date of issue of marketing authorisation valid throughout the European Union |
03/07/2015
|
Contact address |
Product information
20/09/2017 Canigen L4 - EMEA/V/C/004079 - IAIN/0004
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
-
IMMUNOLOGICALS FOR CANIDAE
-
inactivated bacterial vaccines for dogs
Therapeutic indication
For active immunisation of dogs against:
- L. interrogans serogroup Canicola serovar Canicola to reduce infection and urinary excretion;
- L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni to reduce infection and urinary excretion;
- L. interrogans serogroup Australis serovar Bratislava to reduce infection;
- L. kirschneri serogroup Grippotyphosa serovar Bananal/Lianguang to reduce infection and urinary excretion.